Twice-Yearly HIV Prevention Injection Approved by FDA

The FDA has approved Yeztugo (lenacapavir), a groundbreaking twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP), marking a significant advancement in HIV prevention strategies.

A Game-Changer for HIV Prevention

• Just two injections per year
• Over 99% effective at preventing HIV
• Eliminates daily adherence challenges
• Discreet prevention option

How It Works

• Blocks multiple stages of the HIV lifecycle
• Remains active in the body for six months
• Provides consistent protection without daily action
• Works for both prevention and treatment

Clinical Trial Results

• Zero HIV infections among participants receiving lenacapavir
• Significantly better protection than daily oral PrEP
• Well-tolerated with manageable side effects
• High participant satisfaction

Who Can Benefit

• People who struggle with daily medication
• Those in high-risk situations
• Individuals seeking privacy in prevention
• Anyone looking for convenient protection

Addressing HIV Stigma

• Eliminating visible daily pills
• Reducing pharmacy visits
• Providing discreet protection
• Normalizing preventive care

Access and Availability

• Requires healthcare visits twice yearly
• Insurance coverage expanding
• Patient assistance programs available
• Roll-out continuing through 2026

The Road to Ending HIV

This approval represents a major step toward ending the HIV epidemic, making prevention more accessible and achievable for millions at risk.